AI Article Synopsis

  • In-office insertion of the BioMonitor 2 for cardiac monitoring is safe and effective, with successful procedures reported in 77 out of 82 enrolled patients.
  • A significant portion of patients underwent anticoagulation adjustments before the procedure, and the average insertion time was approximately 35 minutes with no major complications.
  • The study results indicate that transferring cardiac monitor insertions from hospitals to office settings could be beneficial, showing good device performance and minimal adverse effects.

Article Abstract

Background: Insertable cardiac monitors are utilized for the diagnosis of arrhythmias and traditionally have been inserted within hospitals. Recent code updates allow for reimbursement of office-based insertions; however, there is limited information regarding the resources and processes required to support in-office insertions. We sought to determine the safety and feasibility of in-office insertion of the BioMonitor 2 and better understand in-office procedures, including patient selection, pre-insertion protocols, resource availability, and staff support.

Methods: Patients meeting an indication for a rhythm monitor were prospectively enrolled into this single-arm, non-randomized trial. All patients underwent insertion in an office setting. Two follow-up visits at days 7 and 90 were required. Information on adverse events, device performance, office site preparations, and resource utilization were collected.

Results: Eighty-two patients were enrolled at six sites. Insertion was successful in all 77 patients with an attempt. Oral anticoagulation was stopped in 20.8% of patients and continued through insertion in 23.4%, while prophylactic antibiotics were infrequently utilized (37.7% of study participants). On average, the procedure required a surgeon plus two support staff and 35 min in an office room to complete the 8.4 min insertion procedure. The mean R-wave amplitude was 0.77 mV at insertion and 0.67 mV at 90-days with low noise burden (2.7%). There were no procedure related complications. Two adverse events were reported (event rate 2.7% [95% CI 0.3, 9.5%]).

Conclusions: In-office insertion of the BioMonitor 2 is safe and feasible. Devices performed well with high R-wave amplitudes and low noise burden. These results further support shifting cardiac monitor insertions to office-based locations.

Trial Registration: clinicaltrials.gov, NCT02756338. Registered 29 April 2016.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161128PMC
http://dx.doi.org/10.1186/s12872-020-01439-8DOI Listing

Publication Analysis

Top Keywords

insertion
8
safety feasibility
8
in-office insertion
8
insertion biomonitor
8
adverse events
8
low noise
8
noise burden
8
patients
5
biomonitor in-office
4
in-office setting
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!